Comparative Pharmacology
Head-to-head clinical analysis: VIZZ versus ZYFREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIZZ versus ZYFREL.
VIZZ vs ZYFREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
ZYFREL is a selective serotonin reuptake inhibitor (SSRI) that inhibits serotonin reuptake at the presynaptic terminal, increasing serotonergic neurotransmission in the CNS.
80 mg orally once daily
500 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours. Steady-state is reached within 4-5 days; accumulation may occur in renal impairment.
12-15 hours, terminal elimination half-life; prolonged in renal impairment (up to 30 hours), requiring dose adjustment.
Primarily hepatic metabolism with renal excretion of metabolites. Approximately 60% of a dose is excreted in urine as metabolites, 30% in feces, and <5% unchanged.
Renal: 65% unchanged; biliary/fecal: 30% as metabolites; 5% other.
Category C
Category C
Unknown
Unknown